2022
Procuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure
Rodriguez J, Tormey C. Procuring rare (珍しい)* Japanese red blood cell units for a bleeding patient with anti-K11 requiring a life-saving procedure. Immunohematology 2022, 38: 96-99. PMID: 36190197, DOI: 10.21307/immunohematology-2022-049.Peer-Reviewed Case Reports and Technical NotesConceptsAmerican Rare Donor ProgramRed blood cell unitsAntigen-positive unitsLife-saving procedurePotential clinical significanceMultiple comorbiditiesKnee amputationExtremity amputationCritical anemiaCase reportAdverse reactionsClinical significanceCell unitsPatient plasmaTransfusion communityGroup OClinical necessityDonor ProgramRBC unitsPatientsAmputationCompatible unitsAnemiaChallenging caseRare eventEfficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients
Olsen GM, Tormey CA, Tseng B, Hendrickson JE, Sostin N. Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal Of Clinical Apheresis 2021, 37: 13-18. PMID: 34698404, DOI: 10.1002/jca.21944.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeSmall fiber neuropathyAdverse eventsPlasma exchangeLower extremity paresthesiasSymptomatic response rateAutoantibody-mediated disorderSkin biopsy resultsSFN symptomsTS-HDSExtremity paresthesiasPeripheral neuropathySymptomatic improvementCase seriesIgM antibodiesMean ageTPE proceduresBiopsy resultsTreatment optionsDisease progressionIgM classVasovagal reactionsClose monitoringLaboratory confirmationResponse rateEarly but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere diseaseCost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood 2021, 137: 969-976. PMID: 33280030, PMCID: PMC7918179, DOI: 10.1182/blood.2020006052.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCombined Modality TherapyCost-Benefit AnalysisDecision TreesDrug CostsDrug Therapy, CombinationFemaleFibrinolytic AgentsHemorrhageHumansImmunosuppressive AgentsLength of StayMaleMarkov ChainsMiddle AgedModels, EconomicMulticenter Studies as TopicPlasma ExchangePurpura, Thrombotic ThrombocytopenicRecurrenceRituximabSingle-Domain AntibodiesStandard of CareUnited StatesYoung AdultConceptsIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeVon Willebrand factorRelapse rateThrombocytopenic purpuraClinical trialsMajor randomized clinical trialsThrombotic microangiopathy leadingEnd-organ damageWillebrand factorPlatelet count recoveryRandomized clinical trialsHealth system costsOne-way sensitivity analysesCost-effectiveness ratioLife-threatening diseaseProbabilistic sensitivity analysesCost-effectiveness analysisHospital lengthCount recoveryPlasma exchangeTPE treatmentTTP patientsImmunomodulatory agents
2020
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study
Goshua G, Pine AB, Meizlish ML, Chang CH, Zhang H, Bahel P, Baluha A, Bar N, Bona RD, Burns AJ, Dela Cruz CS, Dumont A, Halene S, Hwa J, Koff J, Menninger H, Neparidze N, Price C, Siner JM, Tormey C, Rinder HM, Chun HJ, Lee AI. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. The Lancet Haematology 2020, 7: e575-e582. PMID: 32619411, PMCID: PMC7326446, DOI: 10.1016/s2352-3026(20)30216-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBetacoronavirusBiomarkersBlood Coagulation DisordersCoronavirus InfectionsCOVID-19Critical IllnessCross-Sectional StudiesEndothelium, VascularFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMiddle AgedPandemicsPneumonia, ViralPrognosisSARS-CoV-2Vascular DiseasesYoung AdultConceptsCOVID-19-associated coagulopathyNon-ICU patientsIntensive care unitKaplan-Meier analysisSoluble P-selectinCross-sectional studyPlatelet activationHospital dischargeICU patientsSoluble thrombomodulinEndothelial cellsVWF antigenCOVID-19P-selectinSingle-center cross-sectional studyLaboratory-confirmed COVID-19Medical intensive care unitSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesisVon Willebrand factor antigenSoluble thrombomodulin concentrationsVWF antigen concentrationEndothelial cell injurySoluble CD40 ligandMicrovascular complicationsAdult patientsCharacterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status
Balbuena-Merle R, Santhanakrishnan M, Devine L, Gibb DR, Tormey CA, Siddon AJ, Curtis SA, Gallagher PG, Weinstein JS, Hendrickson JE. Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status. Transfusion And Apheresis Science 2020, 59: 102778. PMID: 32439490, PMCID: PMC7483805, DOI: 10.1016/j.transci.2020.102778.Peer-Reviewed Original ResearchConceptsTfh-like cellsNaïve CD4 T cellsSickle cell diseaseCD4 T cellsCD4 T cell subsetsT cell subsetsT cellsCell diseaseRed blood cell alloimmunizationPeripheral blood mononuclear cellsBlood mononuclear cellsCD3/CD28Electronic medical recordsAlloimmunization statusHLA alloantibodiesRBC autoantibodiesRBC alloantibodiesFollicular helperIL-12Mononuclear cellsMedical recordsIL-7Antigen specificityB cellsAlloantibodiesPassive anti‐C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series
Sostin N, Ross R, Balbuena‐Merle R, Hendrickson JE, Tormey CA. Passive anti‐C acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series. Journal Of Clinical Apheresis 2020, 35: 224-226. PMID: 32110829, DOI: 10.1002/jca.21773.Peer-Reviewed Original ResearchConceptsPlatelet transfusionsRh immune globulin administrationRisk/benefit ratioApheresis platelet transfusionImmune globulin administrationRhIG immunoprophylaxisImmune globulinTransfusion supportAlloantibody formationCase seriesNegative recipientsAlloimmunization riskRhIG administrationReproductive agePassive transferPLT transfusionsTransfusionBlood bankBenefit ratioRhIGApheresis PLTsAdministrationImmunoprophylaxisPatientsSettingThe evanescence and persistence of RBC alloantibodies in blood donors
Hauser RG, Esserman D, Karafin MS, Tan S, Balbuena‐Merle R, Spencer BR, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE, Tormey CA, ). The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion 2020, 60: 831-839. PMID: 32061102, DOI: 10.1111/trf.15718.Peer-Reviewed Original ResearchConceptsBlood donorsAntibody persistenceAntibody screenDonor Evaluation Study-IIIHistory of transfusionUS blood centersFit inclusion criteriaPresence of alloantibodiesRecipient EpidemiologyRBC alloantibodiesBlood productsInclusion criteriaSignificant antibodiesBiologic factorsHealthy populationAntibody detectionAntibody identificationAlloantibodiesBlood centersMultiple antibodiesFirst donationAntibody specificityStudy IIIAntibodiesCenter policies
2019
Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease
Balbuena‐Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019, 59: 3219-3227. PMID: 31355970, PMCID: PMC7075520, DOI: 10.1111/trf.15463.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMonocyte subsetsTotal monocytesCell diseaseComplications of SCDRed blood cell alloimmunizationRed blood cell alloantibodiesElectronic medical recordsTransfusion exposureSerum cytokinesIntermediate monocytesRBC alloantibodiesInflammatory milieuCD64 expressionClassical monocytesPeripheral bloodInflammatory functionsMedical recordsAntibody formationClinical significancePatientsMonocytesFlow cytometryLow expressionResponders
2018
Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia
Chandler JB, Siddon AJ, Bahel P, Torres R, Rinder HM, Tormey CA. Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia. Journal Of Clinical Pathology 2018, 72: 177. PMID: 30463936, DOI: 10.1136/jclinpath-2018-205438.Peer-Reviewed Original ResearchPrevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III)
Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Gottschall JL, Hendrickson JE. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study‐III (REDS‐III). Transfusion 2018, 59: 217-225. PMID: 30427537, DOI: 10.1111/trf.15004.Peer-Reviewed Original ResearchConceptsPositive antibody screenDonor Evaluation Study-IIIAntibody screenRisk factorsRecipient EpidemiologyTransfusion historyBlood centersRBC alloantibodiesBlood donorsRed blood cell alloimmunizationCommon antibody specificitiesPrior transfusion historyRBC alloantibody formationSignificant RBC alloantibodiesHistory of transfusionAdjusted odds ratioMultivariable logistic regressionUS blood centersStudy IIIUS blood donorsPotent immune stimulusFuture medical careHealthy US blood donorsPrior transfusionsPrior pregnancyRisk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database
Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, Wu Y, Triulzi DJ, Kleinman S, Hendrickson JE, Study‐III N. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS‐III) database. British Journal Of Haematology 2018, 181: 672-681. PMID: 29675950, PMCID: PMC5991618, DOI: 10.1111/bjh.15182.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnemia, Sickle CellArthritis, RheumatoidBlood DonorsBlood Group AntigensChildChild, PreschoolDatabases, FactualErythrocyte TransfusionFemaleHumansImmunizationInfantIsoantibodiesLupus Erythematosus, SystemicMaleMiddle AgedMyelodysplastic SyndromesRisk FactorsTransfusion ReactionConceptsRed blood cell alloimmunizationRecipient EpidemiologyRecipients databaseSignificant RBC alloantibodiesNegative antibody screenLargest RBCStandardized registryPositive patientsRBC alloantibodiesAntibody screenICD9/10 codesPatient cohortRisk factorsResponder statusCertain diagnosisBlood typeLarger studyAlloimmunizationRhD statusStudy databaseRespondersPatientsDisease associationsPotential correlatesEpidemiology
2017
R634W KIT Mutation in an Adult With Systemic Mastocytosis
Astle JM, Rose MG, Racke FK, Tormey CA, Siddon AJ. R634W KIT Mutation in an Adult With Systemic Mastocytosis. Lab Medicine 2017, 48: 253-257. PMID: 28520972, DOI: 10.1093/labmed/lmx026.Peer-Reviewed Original Research
2016
Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma
Sidhu D, Snyder EL, Tormey CA. Two approaches to the clinical dilemma of treating TTP with therapeutic plasma exchange in patients with a history of anaphylactic reactions to plasma. Journal Of Clinical Apheresis 2016, 32: 158-162. PMID: 27246502, DOI: 10.1002/jca.21475.Peer-Reviewed Original ResearchConceptsTherapeutic plasma exchangeThrombotic thrombocytopenic purpuraSevere allergic reactionsAnaphylactic reactionsTTP exacerbationTTP remissionTreatment strategiesAllergic reactionsVon Willebrand factor (VWF) cleaving proteasePotential treatment strategyPossible treatment protocolReplacement plasmaAdverse eventsAcute treatmentPlasma exchangeThrombocytopenic purpuraSimilar patientsClinical dilemmaTreatment protocolAllergic riskPatientsDonor plasmaADAMTS-13Plasma productsStandard plasma
2015
Variation in vital signs resulting from blood component administration in adults
Gehrie EA, Hendrickson JE, Tormey CA. Variation in vital signs resulting from blood component administration in adults. Transfusion 2015, 55: 1866-1871. PMID: 25867097, DOI: 10.1111/trf.13060.Peer-Reviewed Original Research
2014
Catastrophic basilar artery leukostasis in the setting of acute myeloid leukemia
Raad R, Tormey CA, Siddon AJ. Catastrophic basilar artery leukostasis in the setting of acute myeloid leukemia. Transfusion 2014, 54: 970-970. PMID: 24724788, DOI: 10.1111/trf.12384.Peer-Reviewed Original Research
2013
Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components
Xiao W, Tormey CA, Capetillo A, Maitta RW. Allergic transfusion reactions to platelets are more commonly associated with prepooled than apheresis components. Vox Sanguinis 2013, 105: 334-340. PMID: 23802769, DOI: 10.1111/vox.12063.Peer-Reviewed Original ResearchConceptsAllergic transfusion reactionsTransfusion reactionsATR rateApheresis plateletsPlatelet componentsApheresis componentsAcademic medical centerABO mismatchAdverse eventsAntigen exposurePlatelet transfusionsPlatelet countDonor factorsMedical CenterApheresis productsApheresis unitsPlatelet productsStudy periodTransfusionPlateletsSimilar ratesFurther investigation
2012
Normalized CCND1 expression has prognostic value in mantle cell lymphoma
Siddon AJ, Torres R, Rinder HM, Smith BR, Howe JG, Tormey CA. Normalized CCND1 expression has prognostic value in mantle cell lymphoma. British Journal Of Haematology 2012, 158: 551-553. PMID: 22671703, DOI: 10.1111/j.1365-2141.2012.09181.x.Peer-Reviewed Original Research
2009
Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform
Tormey CA, Peddinghaus ME, Erickson M, King KE, Cushing MM, Bill J, Goodrich T, Snyder EL. Improved plasma removal efficiency for therapeutic plasma exchange using a new apheresis platform. Transfusion 2009, 50: 471-477. PMID: 19804570, DOI: 10.1111/j.1537-2995.2009.02412.x.Peer-Reviewed Original ResearchConceptsSignificant adverse eventsCellular countsPatients D-dimerPlasma-exchange programPlasma removal efficiencyTherapeutic plasma exchangePrimary outcome measureFluid balance measurementsComplement cascade activationPatient's coagulationSecondary outcomesAdverse eventsPlasma exchangeAnticoagulant usageD-dimerClinical trialsFluid replacementOutcome measuresFluid balanceCoagulation systemCOBE Spectra platformFree hemoglobinStudy designWaste plasmaNew apheresis device